Brief: Elicera Therapeutics Acquirer Patent From Immunicum

Elicera Therapeutics AB

05/01/2022 07:15

Jan 5 (Reuters) - Elicera Therapeutics AB  ELIC.ST :
    * ELICERA THERAPEUTICS STRENGTHENS IP PROTECTION FOR ELC-100
THROUGH ACQUISITION OF PATENT FROM IMMUNICUM
    * ACQUIRED PATENT US 9,017,672 B2 - A VIRAL VECTOR USED IN
ITS
CANDIDATE ELC-100 - FROM IMMUNICUM
    * TRANSFER OF PATENT AMOUNTS TO A TOTAL OF 250,000 EUR IN
PAYMENTS, EXCLUDING POTENTIAL MILESTONES
    * ACQUISITION FURTHER STRENGTHENS IP PROTECTION OF ELC-100,
ELICERA'S MOST ADVANCED PROJECT.

Source text for Eikon:  ID:nWkr4rdKww 
Further company coverage:  ELIC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))